Skip to main content

Drug Interactions between Integrilin and ReoPro

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

abciximab eptifibatide

Applies to: ReoPro (abciximab) and Integrilin (eptifibatide)

CONTRAINDICATED: Concomitant use of multiple glycoprotein (GP) IIb/IIIa inhibitors may increase the risk of major bleeding events due to additive anticoagulation.

MANAGEMENT: Some authorities consider concomitant use of multiple GP IIb/IIIa inhibitors to be contraindicated. If concomitant use is considered, close clinical and laboratory observation for bleeding complications, especially at arterial puncture sites, is recommended. Therapy should be immediately discontinued if serious or uncontrollable bleeding occurs.

References

  1. (2001) "Product Information. ReoPro (abciximab)." Lilly, Eli and Company
  2. (2001) "Product Information. Aggrastat (tirofiban)." Merck & Co., Inc
  3. (2001) "Product Information. Integrilin (eptifibatide)." Schering Corporation
  4. Cerner Multum, Inc. "UK Summary of Product Characteristics."
  5. Cerner Multum, Inc. "Australian Product Information."
View all 5 references

Switch to consumer interaction data

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

Therapeutic duplication is the use of more than one medicine from the same drug category or therapeutic class to treat the same condition. This can be intentional in cases where drugs with similar actions are used together for demonstrated therapeutic benefit. It can also be unintentional in cases where a patient has been treated by more than one doctor, or had prescriptions filled at more than one pharmacy, and can have potentially adverse consequences.

Duplication

Glycoprotein iib/iiia inhibitors

Therapeutic duplication

The recommended maximum number of medicines in the 'glycoprotein IIb/IIIa inhibitors' category to be taken concurrently is usually one. Your list includes two medicines belonging to the 'glycoprotein IIb/IIIa inhibitors' category:

  • Integrilin (eptifibatide)
  • ReoPro (abciximab)

Note: In certain circumstances, the benefits of taking this combination of drugs may outweigh any risks. Always consult your healthcare provider before making changes to your medications or dosage.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer